EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Praxis Precision Medicines's enterprise value is $737.66 Mil.
Praxis Precision Medicines's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-125.94 Mil. Therefore, Praxis Precision Medicines's EV-to-EBITDA for today is -5.86.
The historical rank and industry rank for Praxis Precision Medicines's EV-to-EBITDA or its related term are showing as below:
PRAX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.9 Med: -0.27 Max: 0.34
Current: -5.86
During the past 6 years, the highest EV-to-EBITDA of Praxis Precision Medicines was 0.34. The lowest was -5.90. And the median was -0.27.
PRAX's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs PRAX: -5.86
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), Praxis Precision Medicines's stock price is $48.84.
Praxis Precision Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-22.590. Therefore, Praxis Precision Medicines's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Praxis Precision Medicines EV-to-EBITDA Historical Data
The historical data trend for Praxis Precision Medicines's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Praxis Precision Medicines's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Praxis Precision Medicines EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Praxis Precision Medicines's EV-to-EBITDA falls into.
Praxis Precision Medicines's current Enterprise Value is $737.66 Mil.
Praxis Precision Medicines's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-125.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Praxis Precision Medicines's PE Ratio for today is calculated as:
Praxis Precision Medicines's share price for today is $48.84.
Praxis Precision Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.590.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Praxis Precision Medicines EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Praxis Precision Medicines's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Praxis Precision Medicines (Praxis Precision Medicines) Business Description
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRAX has been successfully added to your 